MedicinePharmacologyPharmacotherapyClinical PharmacologyPharmacodynamicsRhinologyAllergic RhinitisAllergy PharmacotherapyNasal Congestion ManagementNasal FormulationsNasal ObstructionNasal PhysiologyAntihistamine PharmacologyCombination Intranasal TherapyIntranasal AntihistaminesNasal Airway FunctionNasal Airway ResistanceNasal PharmacodynamicsNasal SymptomsPerennial Allergic Rhinitis Treatment
Nasal airway resistance and nasal symptoms were evaluated in patients with perennial non-allergic rhinitis before and after vasoconstrictory drugs and placebo taken orally. The patients were partly selected; those suffering mainly from nasal obstruction being tested. Phenylpropanolamine (PPA) in a dose of 100 mg in a sustained-release preparation clearly decreased the nasal airway resistance measured rhinomanometrically. PPA in a dose of 50 mg and combined with an antihistamine had no obvious decongesting effect. Placebo and dihydroergotamine (DHE) in a dose of 5 mg did not decrease the nasal airway resistance PPA (100 mg) and the combined preparation containing PPA in the lower dose (50 mg) taken twice a day in a cross-over, double-blind study significantly reduced nasal obstruction, secretion, and sneezing compared with placebo. Side effects of PPA are discussed.
14
Peter Borum · Journal of Allergy and Clinical Immunology · 1979 · 148 citations
Role of the Vidian Nerve in Nasal Allergy
Akiyoshi Konno, Kiyoshi Togawa · Annals of Otology Rhinology & Laryngology · 1979 · 118 citations
Medicine, Otolaryngology, Surgery +15